Category: 乳癌研究

Phase 3 randomized, double-blind study in first-line ER+ (≥1%), HER2− advanced/metastatic breast cancer comparing palazestrant + ribociclib vs letrozole + ribociclib. Includes key inclusion/exclusion criteria and dosing details. Contact Hong Kong United Oncology Centre.

NCT07085767: OPERA-02 Study

The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with estrogen receptor-positive (ER+), HER2-negative (HER2−) advanced/metastatic breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the eligibility criteria for this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

立即閱讀
December 18, 2025 No Comments

NCT06966700: Trofuse-032/MK2870-032 Research

Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with high-risk early-stage triple-negative breast cancer (TNBC) or hormone receptor-weak positive/HER2-negative breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the criteria for participation in this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

立即閱讀
November 19, 2025 No Comments

NCT06393374: TroFuse-012 Research

The Hong Kong Joint Oncology Centre is now recruiting triple negative breast cancer (TNBC) patients to participate in the Phase 3 clinical study NCT06393374. For those who have not achieved pathological complete response (pCR), MK-2870 combined with Pembrolizumab treatment will be used, with free medication and imaging scanning fees. Get in touch with us immediately to inquire about eligibility, research process, and risks.

立即閱讀
March 10, 2025 No Comments
香港聯合腫瘤中心 - 專業乳腺癌治療與臨床研究服務

NCT06018337: DB-1303

The United Cancer Centre of Hong Kong is now recruiting patients with low HER2 expression and hormone receptor-positive metastatic breast cancer to participate in the phase 3 clinical study NCT06018337, using DB-1303 or chemotherapy regimen, drugs and image scans are free of charge. To understand the eligibility for application, the research process and the risks, please contact us immediately for details.

立即閱讀
May 2, 2024 No Comments

NCT06016738: OPERA-01 Research

Recruit patients with ER+, HER2-advanced or metastatic breast cancer after treatment with endocrine and CDK4/6 inhibitors to participate in the clinical study of the research drug OP-1250 (Palazestrant).

立即閱讀
December 21, 2023 No Comments
臨床研究-Alpelisib (BYL719)

Alpelisib (BYL719)

Patients with HR+ and HER2-advanced breast cancer with PIK3CA mutations were recruited to receive Alpelisib (BYL719) clinical research drugs.

立即閱讀
April 18, 2023 No Comments
臨床研究-Sacituzumab Govitecan (Trodelvy®) 和 Pembrolizumab

Sacituzumab Govitecan (Trodelvy®) and Pembrolizumab

Recruit untreated patients with locally advanced inoperable or metastatic PD-L1-positive triple-negative breast cancer who have not received treatment to participate in clinical studies of Sacituzumab Govitecan (Trodelvy®) and Pembrolizumab investigational drugs.

立即閱讀
April 17, 2023 No Comments
臨床研究-Magrolimab

Magrolimab

Recruit patients with metastatic triple-negative breast cancer who have not received treatment to receive Magrolimab clinical research drugs

立即閱讀
April 17, 2023 No Comments
臨床研究-ARX788

ARX788

Recruit patients with drug-resistant or refractory HER2-positive metastatic breast cancer with T-DM1, T-DxD, or Tucatinib

立即閱讀
April 17, 2023 No Comments